Metabolic Liver Disease

Latest Articles

Investigational Ubrogepant Does Not Confer Hepatotoxicity in Healthy Individuals

By

Brandon May

Publish Date November 8, 2019

Investigators aimed to evaluate the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosing in healthy participants.

Tesamorelin May Aid Patients With HIV, Fatty Liver Disease

Publish Date October 23, 2019

Tesamorelin significantly reduced hepatic fat fraction compared with placebo

Lanifibranor Gets Fast Track Status for Non-Alcoholic Steatohepatitis

By

Brian Park, PharmD

Publish Date October 8, 2019

The FDA has granted Fast Track designation to lanifibranor (Inventiva) for the treatment of non-alcoholic steatohepatitis.

Examining Serum Hepatic Enzymes, Lipid Profile, and Glycemic Control in T2D

By

Tyler Rice

Publish Date October 1, 2019

Researchers found that mean hepatic enzyme levels were jointly and significantly associated with poorly controlled T2D.

Fluoride Exposure Tied to Kidney, Liver Function Changes in Youth

Publish Date September 10, 2019

This study’s findings suggest that there may be potential kidney and liver health concerns to consider when evaluating fluoride use and appropriate levels in public health interventions.

Diagnosing Fibrosis Stage in NAFLD: Transient Elastography Better Than Point Shear Wave Elastography

By

Gastroenterology Advisor Contributing Writer

Publish Date August 1, 2019

Study results showed that transient elastography was good for the diagnosis of all fibrosis stages and was superior compared with point shear wave elastography for the diagnosis of fibrosis stages ≥F2 and ≥F3.

ARO-AAT Receives Fast Track Status for Treatment of Rare Genetic Liver Disease

By

Brian Park, PharmD

Publish Date July 23, 2019

The FDA has granted Fast Track designation to ARO-AAT an investigational treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency